NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new patent application covering a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated through Sarborg's quantum-enabled PRISM platform.
According to Sarborg, the filing organizes its claimed combinations around six distinct application configurations, each defined by the growth stage of application, the delivery route, the dose and timing, and the agronomic target addressed. Within this framework, Sarborg has identified 606 field-applicable combinations, each assigned to a primary configuration and, where applicable, a secondary configuration. The combinations were identified computationally through PRISM's cross-species connectivity mapping engine, powered by SarborgQ, Sarborg's dedicated quantum computing division.
CDT believes this filing represents another important milestone in the continued development of Sarborg's Signature Intelligence platform and demonstrates the practical application of SarborgQ to a new sector following its recent launch. Applying quantum computing and agentic reasoning to agricultural combination discovery has the potential to accelerate intellectual property generation, expand Sarborg's addressable markets beyond pharmaceuticals, and strengthen the commercial potential of its cross-sector Signature Intelligence platform. CDT acquired 1,020 shares in Sarborg on February 20, 2026, representing 20% of the issued share capital at that time.
“We are pleased to see Sarborg continuing to execute against its strategic roadmap and further expand the practical applications of its Signature Intelligence platform,” said Andrew Regan, Chief Executive Officer of CDT Equity. “The application of SarborgQ to agricultural combination discovery demonstrates how Sarborg is seeking to leverage quantum computing to accelerate intellectual property generation beyond pharmaceuticals.”
A copy of Sarborg’s full announcement is available at: Sarborg Files New Patent Application Extending Quantum-Enabled PRISM to Field-Deployable Combination Interventions for Sugarcane & www.sarborg.com/news.
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
[email protected]